Connect with us

Media & Technology

Be Water, Happy Mellow Beverage; the Rise of Greene Concepts Inc. (OTC Pink: INKW)

Published

on

Greene Concepts Inc. (OTC Pink: INKW) is making a powerful run up the charts in recent days exploding over a penny and emerging as a volume leader in small caps trading over $4.5 million in dollar volume on Monday alone. Microcapdaily reported on the stock last summer when it was a little over .001.

INKW has made significant progress in recent months recently securing an agreement with the U.S. government as a government vendor through the Defense Logistics Agency (DLA) and System for Award Management (SAM). Additionally, the Company received approval as a vendor through the Federal Emergency Management Agency (FEMA) to provide products during national emergencies. Green Concepts has created its new Be Water brand along with placement approval on Amazon.com plus two new labels for placement in the enormous Chinese market. INKW has already started negotiations to sell Be Water in India as well as secured an agreement with SoluScience to create the new Happy Mellow beverage enhancer which will soon be selling on Amazon and at the Subscribe and Save Water Club Subsidiary. Sales are rising quickly and the Company earned a profit last quarter.

Greene Concepts Inc. (OTC Pink: INKW) is a publicly traded company. Through its recently acquired wholly owned subsidiary, Mammoth Ventures Inc., the Company has entered the specialty beverage and bottling business and is an emerging leader in the global scientifically formulated beverage industry. Through its subsidiary Water Club, Inc. we intend to pursue subscription-based delivery of water and scientifically formulated beverages directly to the consumers home and market the convenience of this service thru social media affiliate marketing partners.

Shortly after acquiring its bottling and beverage plant in North Carolina Greene Concepts launched its first brand, its premium bottled water called “Be Water” and received regulatory approval to begin production and distribution. More recently Greene Concepts launched an Immune Support beverage with CBD, CBN, and CBG. The beverage label says BE Happy, Be Mellow, Be Hemp, and Be Water. Developed along with its partner SoluSciences Happy Mellow formula blend is an industry changing water soluble hemp extract formula never before seen in a beverage in the marketplace and was created to produce a fast-acting prolonged active ingredient release to improve and maximize total body health. SoluSciences, Happy Mellow brand consists of high-water solubility which reduces the limitations often seen in other companies that use oil-based compounds in their design. Greene Concepts will produce a more concentrated and stronger formula than other like products on the market. Greene Concepts will sell the Happy Mellow highly concentrated formula in both 16.9 oz (.5L) and 8 oz (.24L) bottles which only require 10 mg of hemp extract for maximum potency versus most hemp extract drinks which have 25 mg. Happy Mellow is patent pending. The beverage also has Immune Support Ingredients which will include: Vitamin C, Vitamin D, Zinc, and Selenium along with hemp extract and flavoring. The Happy Mellow beverage is formulated to contribute to the bodys own natural healing processes of anxiety and joint pain relief, anti-inflammation, muscle relaxation, stress relief, immune support, and many other benefits.

To Find out the inside Scoop on INKW Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

INKW

Greene Concepts CEO Lenny Greene is a serious go getter who has been working hard behind the scenes strengthening the share structure and creating shareholder value. To this end Mr. Greene retired 360 million shares and initiated a stock buy-back program as well filed an attorney letter to garner current reporting status for INKW. Recently Greene Concepts secured a new distribution agreement with Harold Wingert, the founder and CEO of Sunflower Consulting Group in California. Greene Concepts also secured a new distributor in Louisiana with multiple local convenient store connections who is currently receiving inventory. Additionally, the Company is adding a distributor in Atlanta, Georgia along with David Day, Founder of New World Health and wellness in Oregon.

INKW has been making big moves over the past year; the Company launched its production plant in March 2020 following 16 months of plant restoration (up to 192 million bottle capacity ‘8 million cases’ with current equipment) with room for additional capacity. The Company also purchased the land surrounding the bottling plant to include seven production wells for unlimited water resource production capacity to include bottling and industrial water provision.

INKW finalzied an agreement with the U.S. government as a government vendor through the Defense Logistics Agency (DLA) and System for Award Management (SAM). Additionally the Company received approval as a vendor through the Federal Emergency Management Agency (FEMA) to provide products during national emergencies. The Company created its new Be Water brand along with placement approval on Amazon.com plus two new labels for placement in the enormous Chinese market. INKW has already started negotiations to sell Be Water in India as well as secured an agreement with SoluScience to create the new Happy Mellow beverage enhancer which will soon be selling on Amazon and at the Subscribe and Save Water Club Subsidiary. The Company has also partnered with New World Health and Wellness to proliferate company sales in the CBD industry and offer healthier solutions to the public which will soon be selling on Amazon.

Sales are picking up too; for the Period Ending October 31, 2020. Sales for the quarter equal $101,022 vs. $3,249 for the same period in 2019. Total Assets for the quarter equals $4,380,881 versus $3,250,900 for the same period in 2019. Also, for the same period, the company earned a net income of $39,890 versus net loss of -$125,559 for the same quarter in 2019.

Lenny Greene, CEO of Greene Concepts highlights, “I am confident Greene Concepts is on the right track to achieve its goals and am encouraged by the progress we are making as a company. The global bottled water market is expected to reach $350 billion by next year and $410 billion by 2024 and we are ready to carve out a nice piece of that market. There are many reasons for optimism in 2021. As we increase our partnerships and distribution channels this will lead to profitable growth through increased sales penetration to convenience stores, retailers, and small businesses. We are poised to begin our new Water Club Subscribe and Save service where consumers may receive a continuous supply of our bottled Be Water, Happy Mellow and our newest Hemp Retinol products along with Hemp roll-on’s and Creams shipped directly to their front door.I thank you, our 5,000 shareholders, for your continued support. We are proud of our progress in 2020 and excited about what the future holds for Greene Concepts (INKW) and our Shareholders in 2021.”

We have a Monster Pick Coming. Subscribe Right Now!

INKW is making a powerful run up the charts in recent days exploding over a penny and emerging as a volume leader in small caps trading over $4.5 million in dollar volume on Monday alone. Microcapdaily reported on the stock last summer when it was a little over .001. Beverage stocks have a long history of historic moves in small caps and INKW has been no exception in the past. Greene Concepts thru its wholly-owned subsidiary Mammoth Ventures Inc., owns and operates a bottling and beverage facility in Marion, North Carolina. The Marion, NC facility is a 60,000 sq. ft. bottling and beverage plant that is located within the boundaries of the Pisgah National Forest. The facility sits on 4.5 acres of land and has as its water sources a combination of 7 spring and artesian wells that are fed from a natural aquifer that is located deep below the Pisgah National Forest. As of Q2 2020 Greene Concepts is able to produce well beyond the previous limit of 192 million bottles per year (8 million cases) in preparation for significant expansion to meet pending demand. INKW has a solid crew of penny stock speculators behind it currently bidding the stock higher. INKW has made significant progress in recent months recently securing an agreement with the U.S. government as a government vendor through the Defense Logistics Agency (DLA) and System for Award Management (SAM). Additionally, the Company received approval as a vendor through the Federal Emergency Management Agency (FEMA) to provide products during national emergencies. Green Concepts has created its new Be Water brand along with placement approval on Amazon.com plus two new labels for placement in the enormous Chinese market. INKW has already started negotiations to sell Be Water in India as well as secured an agreement with SoluScience to create the new Happy Mellow beverage enhancer which will soon be selling on Amazon and at the Subscribe and Save Water Club Subsidiary. Sales are rising quickly and the Company earned a profit last quarter. We will be updating on INKW when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with INKW.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in INKW either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Featured

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) Secure Partnership

Published

on

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan's proprietary target discovery platform.

TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.

Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities

Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable. 

The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable. 

Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand: 

Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.

As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.

To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.

Here are a couple of blurbs from the management team

“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”

“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”

What’s retail saying?

As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques. 

Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day.  Compared to the ~27M shares traded at the time of writing, that’s a massive shift.

We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

ContraFect Corp (NASDAQ: CFRX): A Low Float Runner

Published

on

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual.

On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.

However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.

To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Summary of latest PR on April 26, 2023

ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.

What are retail traders saying?

https://twitter.com/RealWillTopol/status/1651553835801001986?s=20

It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them. 

We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits. 

However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.

About ContraFect Corp (NASDAQ: CFRX)

ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.

We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.